Infant dies in ATV crash, N.S. RCMP says alcohol may be a factor
An infant has died and three others, including another child, were taken to hospital following an ATV crash in Forties, N.S., on Monday.
Being able to simply turn off your allergies sounds like a dream—but a new discovery shaking the foundations of allergy research might have just made that possible.
For the first time, researchers say, a team has isolated a cell responsible for remembering allergies and triggering the production of antibodies that cause the allergic reaction.
It’s a “ground-breaking discovery,” researchers say, which paves way for treatments that could potentially shut off an allergic response completely.
“Before the discovery of this cell, we didn't really know exactly what it was that we were trying to go after. And so now, basically, we have the smoking gun, we know this is the thing that is keeping people allergic,” Josh Koenig, assistant professor with McMaster’s Department of Medicine and co-lead of the study, told CTVNews.ca in a phone interview Tuesday.
“And our job now is to find ways to inactivate it.”
Researchers with McMaster University and Denmark-based pharmaceutical company ALK-Abello discovered that a type-2 memory B cell (MBC2) was making the antibodies found in allergic reactions. People without allergies had very few memory B cells, if any, researchers found.
B cells are one of the types of immune cells that work to protect our body during an immune response.
Prior to this research’s publication in the peer-reviewed journal Science Translational Medicine this Wednesday, this specific type of cell had never been described before, Koenig said, adding that their work is being published parallel to a second study confirming the presence of this cell in children with peanut allergies.
Allergies have always been a bit of an anomaly in the medical world, because it’s not a disease that is continually progressing and spurring a constant immune response, nor a chronic condition that needs ongoing management.
“With allergies, people can avoid their food for a long time, but they still stay allergic, and how the immune system remembers how to stay allergic like that is something that's not well understood,” Koenig said.
Researchers have been working on this puzzle for around 15 years, he said.
“We know that how the immune system works is every time it sees the allergen through, say, an accidental exposure, that the immune systems will wake up, and it will start making more of the thing that makes you allergic, which are antibodies. Antibodies make people allergic,” Koenig said.
When a person with a serious shellfish allergy goes into anaphylactic shock after accidentally eating a piece of shrimp, the anaphylactic reaction is these IGE antibodies at work. But their production has to be triggered by another cell.
“We kind of started by wondering, ‘Well, is there a type of cell that will hold this memory that will basically be the ones who contribute to that allergic antibody production? And the answer turned out to be yes.”
In order to find out whether there was a specific foot soldier among the memory B cells that was in charge of remembering allergies, researchers created a type of fluorescent molecule called, tetramers, out of allergens to locate memory B cells, building on previous research by Koenig and his team. They also used single cell sequencing, using computers to arrange more than 90,000 cells into groupings based on their physical similarities.
“Basically, we took a bunch of B cells out of people's blood who are allergic,” Koenig said. “And then we looked at every single cell and looked at all of the genes that that cell makes.”
A big portion of their data relied on clinical samples from ALK-Abello, which had a cohort of people taking an immunotherapy drug for their allergies.
“Basically, they were taking a little bit of their allergen every single day,” Koenig explained. “And in the first little while of taking that therapy, their immune system actually makes many more allergic antibodies.”
This allowed researchers to study the production of allergic antibodies without actively triggering dangerous allergic responses.
The immunotherapy drug addressed allergies to birch, a seasonal allergy, or allergies to dust, “something that’s common for asthmatics,” Koenig said.
“In both of those contexts, we found those cells.”
Researchers also looked at people with peanut allergies, one of the most common food allergies. MBC2 was found to be producing antibodies in those people as well—suggesting this cell could be the culprit behind a wide scope of allergies.
“What underlies these different conditions is the same thing,” Koenig said. “And so how we're thinking about it is that basically any allergy that has these allergic antibodies—which is pretty well all of them—these are the ones that have these types of cells (MBC2).”
The implications are vast, researchers say.
If an allergic reaction is the destructive stampede caused by someone shouting ‘fire’ in a packed auditorium, MBC2 is the person who yelled. It’s not the cause of the damage itself, but if it could be stopped from triggering the production of allergic antibodies, there would, theoretically, be no allergic reaction.
“The discovery really pinpoints two potential therapeutic approaches we might be able to take,” Kelly Bruton, a postdoctoral fellow at Stanford University, said in a press release. Bruton co-led the research with Koenig when she was a PhD student at McMaster.
“The first is targeting those MBC2s and eliminating them from an allergic person. The other option could involve changing their function and have them do something that’s not going to be ultimately harmful when the individual is exposed to the allergen.”
Koenig said his colleagues are already working on understanding how to inactivate the cell, and that many other pharmaceutical companies will be able to come up with their own drugs that target this cell to shut it off without damaging the surrounding cells.
So will we start seeing medication that can shut off a peanut allergy on the shelves any day now? Not yet, Koenig says.
Ensuring the safety and efficacy of new drugs takes a long time, and so we’re looking a “a minimum of five years” to even understand how to apply this information into a drug and start the regulatory process.
“If there's stuff that ends up getting into these clinical trials from this work, that five to 10 year time point is possible,” Koenig said. “Or if we need to make completely new things, it may be even longer than that.”
This research received funding from the Schroeder Allergy and Immunology Research Institute, Food Allergy Canada, ALK Abelló A/S, the Zych Family, the Satov Family, the Canadian Allergy Asthma and Immunology Foundation, and the Cancer Research Institute Irvington Postdoctoral Fellowship, according to the release.
There’s still a huge host of unanswered questions about allergies, Koenig said.
For instance, researchers don’t know what causes some allergic reactions to be so severe, or why the same person might have varying levels of severity in their allergic reactions over the span of their life.
We also still don’t know why the body produces MBC2 in the first place in people with allergies. The mistake likely happens even earlier, with the body seeing something it doesn’t recognize and then creating MBC2 in order to remember that the body is suspicious of a certain substance.
“We think that they are really mediators of this disease, or they're really the ones that are keeping people allergic in that long term,” Koenig said. “How it emerges, how the cell comes to exist, is still a mystery that we need to figure out.”
But we don’t need to understand why the severity varies or why MBC2 emerges in order to target it for therapies.
“The really important thing is, before, we couldn't even see the horizon, didn't know what it was that we were trying to (target),” Koenig said. “Now, the horizon’s in view. And we know exactly where we need to go and what we need to do.”
An infant has died and three others, including another child, were taken to hospital following an ATV crash in Forties, N.S., on Monday.
Car manufacturer Nissan has issued a do-not-drive warning for some older vehicles equipped with Takata airbag inflators, due to the risk of explosion during a crash.
Jury deliberations began Wednesday in Donald Trump’s hush money trial, placing the outcome of the history-making case in the hands of a dozen New Yorkers who have vowed to be fair and impartial in the face of their unprecedented task.
Canadian figure-skating icon Tessa Virtue is expecting her first child, she revealed via social media Tuesday.
A professional kiteboarder from P.E.I. says he has been seriously injured in a shark attack that occurred while he was snorkelling in the Turks and Caicos Islands last week.
It’s a floating city exclusively home to the 1 per cent, a playground for multimillionaires and billionaires that circumnavigates the world's oceans.
Get ready to feel the heat, Canada. Weather experts are predicting more sunshine and warmer temperatures for the summer.
Canada has announced an $11.2-billion contract to improve training platforms for the military, including the purchase of 70 training aircraft for the Future Aircrew Training program.
The Edmonton Oilers are shaking things up. Down 2-1 in the NHL's Western Conference final to the Dallas Stars, head coach Kris Knoblauch confirmed there would be lineup changes for tonight's Game 4.
Debby Lorinczy remembers her father as an amazing person and as a man who also made an amazing discovery.
Abigail Strate is a member of the Canadian national ski jumping team and an Olympic bronze medallist. She's also a certified beekeeper.
It's been a long time coming, but one Oilers superfan is hoping this will be the year he gets to touch up his massive Stanley Cup back tattoo.
A man's daring rescue of a newborn wild foal that was trapped after falling down a steep embankment was caught on video over the weekend.
A Winnipeg pinball wizard is heading to the granddaddy of them all – the IFPA World Pinball Championship.
It’s the chance of a lifetime for a group of Ottawa athletes who are getting ready to represent Team Canada at the World Junior Ultimate championships in the United Kingdom.
Parishioners at Holy Trinity Anglican Church are praying for a monetary miracle, as their historic place of worship could collapse at any moment.
A Saskatchewan man made it to the summit of Mount Everest earlier this month.
IAMGOLD’s Cote Gold open pit mine, located off Highway 144 between Timmins and Sudbury, had its official ribbon-cutting ceremony this week as production ramps up.